Sugi Predict

Sugi Predict / Compounds / SCHEMBL7419212

SCHEMBL7419212

SCHEMBL7419212

COC(=O)C1C(=O)C2CCC1C2

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.45
▸ HIF1A Q16665 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.37
▸ CHRNB2 P17787 1/20 0.35
▸ CHRNB4 P30926 1/20 0.35
▸ CHRNA3 P32297 1/20 0.35
▸ CHRNA7 P36544 1/20 0.35
▸ CHRNA4 P43681 1/20 0.35
▸ SLC6A3 Q01959 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ CHRM2 P08172 1/20 0.34
▸ CHRM4 P08173 1/20 0.34
▸ CHRM3 P20309 1/20 0.34
▸ POLB P06746 1/20 0.33
▸ BRD4 O60885 1/20 0.33
▸ TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18527521 1.00 CYP1A2 (0.45) CYP1A2HIF1AALDH1A1CHRNB2CHRNB4
SCHEMBL14484945 0.81 ALDH1A1 (0.39) CYP1A2ALDH1A1KMT2AMEN1CYP2C9
SCHEMBL15840887 0.76 ALDH1A1 (0.36) CYP1A2ALDH1A1KMT2AMEN1CYP2C19
SCHEMBL15106250 0.75 CHRNB2 (0.47) CYP1A2HIF1AALDH1A1CHRNB2CHRNB4
SCHEMBL15106248 0.75 CHRNB2 (0.47) CYP1A2HIF1AALDH1A1CHRNB2CHRNB4
SCHEMBL1432885 0.73 ALDH1A1 (0.31) ALDH1A1
SCHEMBL6765079 0.71 SLC6A3 (0.42) CYP1A2HIF1AALDH1A1CHRNB2CHRNB4
SCHEMBL19807408 0.71 SLC6A3 (0.42) CYP1A2HIF1AALDH1A1CHRNB2CHRNB4
SCHEMBL22579795 0.69 ALDH1A1 (0.41) CYP1A2ALDH1A1KMT2AMEN1CYP2C9
SCHEMBL12506436 0.68 ALDH1A1 (0.32) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092053-A1 KHK INHIBITORS GILEAD SCIENCES INC (US) 2026-04-02 — — US disclosed
EP-4703362-A1 COMPOUND CONTAINING OXO-PYRIDO-ALIPHATIC RING OR ALIPHATIC HETEROCYCLIC STRUCTURE, AND MEDICAL USE THEREOF Chengdu Sibeibo Pharmaceutical Technology Co., Ltd (CN) 2026-03-04 — — EP disclosed
EP-4681774-A2 KHK INHIBITORS Gilead Sciences, Inc. (US) 2026-01-21 — — EP disclosed
EP-4313967-B1 KHK INHIBITORS GILEAD SCIENCES INC (US) 2025-11-12 — — EP disclosed
US-12410160-B2 KHK inhibitors GILEAD SCIENCES, INC. (US) 2025-09-09 — — US disclosed
WO-2025061141-A1 PHARMACEUTICAL COMPOSITION HAVING IMPROVED PHARMACOKINETIC PROPERTIES 成都思倍博医药科技有限公司 2025-03-27 — — WO disclosed
CN-119306709-A Synthesis method of compound containing oxo-pyrido alicyclic heterocycle or alicyclic structure and novel intermediate 成都思倍博医药科技有限公司 2025-01-14 — — CN disclosed
WO-2024222889-A1 COMPOUND CONTAINING OXO-PYRIDO-ALIPHATIC RING OR ALIPHATIC HETEROCYCLIC STRUCTURE, AND MEDICAL USE THEREOF 成都思倍博医药科技有限公司 2024-10-31 — — WO disclosed
EP-4313967-A1 KHK INHIBITORS GILEAD SCIENCES, INC. (US) 2024-02-07 — — EP disclosed
US-20230079863-A1 KHK INHIBITORS GILEAD SCIENCES, INC. 2023-03-16 — — US disclosed
US-20170050958-A1 Cycloalkyl-Linked Diheterocycle Derivatives PFIZER INC. (US) 2017-02-23 — — US disclosed
WO-2016049097-A1 INHIBITORS OF HIF PROLYL HYDROXYLASE MERCK SHARP & DOHME CORP. (US) 2016-03-31 — — WO disclosed
WO-2015188152-A1 NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2015-12-10 — — WO disclosed
WO-2015188152-A1 NOVEL EP4 AGONISTS AS THERAPEUTIC COMPOUNDS ALLERGAN, INC. (US) 2015-12-10 — — WO disclosed
WO-2015028848-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS MULTI-KINASE INHIBITORS Piramal Enterprises Limited (IN) 2015-03-05 — — WO disclosed
US-20100234363-A1 HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2010-09-16 — — US disclosed
US-20100234363-A1 HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2010-09-16 — — US disclosed
EP-2208728-A1 HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 -HYDROXYSTEROID DEHYDROGENASE Institute Of Medicinal Molecular Design, Inc. (JP) 2010-07-21 — — EP disclosed
EP-1230225-A2 PHARMACEUTICALLY ACTIVE 4-SUBSTITUTED PYRIMIDINE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-08-14 — — EP disclosed
WO-2001032632-A2 PHARMACEUTICALLY ACTIVE 4-SUBSTITUTED PYRIMIDINE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092053-A1 KHK INHIBITORS KHK, SLC5A2, HK1 CYP1A2 774/4885HIF1A 1351/4885ALDH1A1 700/4885
US-20230079863-A1 KHK INHIBITORS KHK, KHDRBS1, NADK CYP1A2 546/4885HIF1A 1153/4885ALDH1A1 1520/4885
US-12410160-B2 KHK inhibitors KHK, KHDRBS1, NADK CYP1A2 546/4885HIF1A 1153/4885ALDH1A1 1520/4885
US-20100234363-A1 HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE HSD11B1, HSD11B2, HSD3B1 CYP1A2 130/4885HIF1A 4474/4885ALDH1A1 165/4885
US-20170050958-A1 Cycloalkyl-Linked Diheterocycle Derivatives CCNY, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCND2 CYP1A2 1768/4885HIF1A 3052/4885ALDH1A1 2190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.